Introducing
a new haemostat
with outstanding
tissue adhesion

TenaTac®

Haemostatic absorbable gelatine patch with surface modification for increased tissue adhesion

TenaTac®

Haemostatic absorbable gelatine patch with surface modification for increased tissue adhesion

Fig. 1: TenaTac®

TenaTac® uses an innovative technology that enhances the adhesion of a conventional gelatine sponge to an area of surgical bleeding, ensuring that the product will remain in situ to maximise haemostatic control.

This novel technology has the potential to reduce post-operative bleeding complications. Selentus' technology is based upon a unique surface modification in which no new materials are added.

Patents granted in Europe (EP3362110); U.K. (GB 2543307), U.S.A (US 10,653,821), Brazil (BR 112018007612-0 B1) and Japan (JP 6854825) and pending worldwide.

The TenaTac® Advantage

- ✔ Laser-guided surface modification ensures TenaTac® adheres strongly to tissue
- ✔ Controls bleeding rapidly and seals off bleeding sites
- ✔ Greatly reduced risk of migration from site of application
- ✔ Ready-to-use dry
- ✔ Free from blood-derived proteins
- ✔ Easy to apply
- ✔ Cost-effective

Fig. 2: Over 1000 columns attach to the wound increasing adhesion. TenaTac® is flexible and compresses to 1-2 mm in depth.

Mode of Action

TenaTac® has a unique surface modification created with high precision. The surface of the patch is divided into over 1000 columns. This leads to a 10-fold increase in surface area, greatly increasing the interaction between the product and the underlying tissue. See figure 2. The flexible columns conform to the variations in tissue surface and act independently to resist shear forces that may dislodge a normal sponge in the peri-operative period.

TenaTac® becomes pliable when moist and compresses to 1-2mm. Its flexibility in dry form can be improved by light compression thus facilitating minimal invasive application.

TenaTac®

Haemostatic absorbable gelatine patch with surface modification for increased tissue adhesion

Evidence of superior performance

In a controlled, hepatic injury model, undertaken by an independent surgical team, TenaTac® consistently outperformed a leading comparator sealant both in terms of reducing bleeding severity and greatly improved adhesion. See figure 3 and figure 4.

Better adhesion

Fig. 3: TenaTac® demonstrates significantly stronger tissue adhesion than comparator (a leading haemostatic sealant)



In the adhesion test, TenaTac® was graded as having the highest level of adhesion in 94% of the cases, whilst a leading comparator only achieved this in 19% of cases ($p<0.001$). In addition, TenaTac® never scored below 60% for adhesion, whilst the comparator did a third of the time. Data on file.

Better bleeding control

Fig. 4: TenaTac® reduces bleeding severity score following hepatic injury compared to comparator (a leading haemostatic sealant)



TenaTac® significantly reduced the severity of bleeding seen in the study at 6 minutes by 53% vs. comparator, and this had increased to over 90% at 9 minutes. ($p=0.002$). Data on file.

The pre-clinical study results are published in the World Journal of Surgery and Surgical Research: Physical Modification of a Gelatin Sponge Creates a Very Adhesive, Rapidly Absorbable, BloodFree Hemostat. World J Surg Surgical Res. 2023; 6: 1500

Click this button for immediate access to the publication.



Fig. 5 and fig. 6: TenaTac® resisted removal and effectively controlled the bleeding in 100% of applications. TenaTac® compresses to 1-2mm in depth.

Clinical evaluation

TenaTac® was evaluated in a range of major surgical procedures in a broad variety of territories worldwide. These evaluations are ongoing. In this range of interventions, the most prominent ones were in neurosurgery, spine surgery, thoracic surgery, liver surgery, urology surgery and digestive surgery. TenaTac® was assessed against a range of parameters including adhesion to the bleeding site, haemostatic control and ease of use.

The results of the first series of 63 evaluations are published in the International Journal of Surgery Open: Assessment of the efficacy of a novel adhesive haemostat using real world, case series data collection. International Journal of Surgery Open, Volume 60, 2023, 100690.

Click this button for immediate access to the publication.

TenaTac® approval rating

Would recommend (% Yes)



Collection of Clinical Evaluations is ongoing. Until November 2023 a total of 109 evaluations are analysed and resulted in the TenaTac® approval rating.

TenaTac®

Haemostatic absorbable gelatine patch with surface modification for increased tissue adhesion

selentusscience

Selentus develops innovative haemostatic technologies for better surgical outcomes. In addition to TenaTac®, Selentus is developing a pipeline of other products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials.

CuraMedical B.V. acquired the manufacturing rights of **TenaTac®,** which is developed by the British company **Selentus Science Ltd. CuraMedrix B.V.,** a marketing company under the **CuraGlobe Holding Group,** acquired the distribution rights for **TenaTac®** for the majority of the countries where **CuraMedical B.V.** markets the present range of (absorbable) haemostats.

CuraMedical B.V. is a Dutch medical device company that operates in the wound management sector and specialises in the development, manufacturing and marketing of haemostatic agents. Continuously striving to offer exceptional quality and value, the company uses leading-edge technology to ensure an outstanding and reliable product performance.

CuraMedical B.V. entered the healthcare market in 1995 with **CuraSpon®,** an absorbable haemostatic agent based on pharmaceutical gelatine. The haemostatic product line was further developed with the introduction of **CuraCel®,** a range of oxidised regenerated cellulose haemostats, and **CuraTamp®,** an oxidised cellulose haemostat and **CuraWax®,** a non-absorbable haemostatic bone wax.

Preparation	Dimensions	Reference	Packaging
TenaTac®	80 x 50 x 10 mm	TT-08050	Boxes of 5 pieces
TenaTac®	50 x 40 x 10 mm	TT-05040	Boxes of 5 pieces
TenaTac®	40 x 25 x 10 mm	TT-04025	Boxes of 5 pieces

Other sizes on request

BTT001.04.EN
Rev.2023-10

Manufacturer
CuraMedical B.V.
Industrieweg 6B
1566 JP Assendelft
The Netherlands

Phone: +31(0)75 657 18 85
Fax: +31(0)75 657 11 84
Email: sales@curamedical.com
Website: www.curamedical.com

Distributor
CuraMedrix B.V.
Industrieweg 13-1
1566 JN Assendelft
The Netherlands

Phone: +31(0)75 657 18 85
Fax: +31(0)75 657 11 84
Email: sales@curamedrix.com
Website: www.curamedrix.com